Urological impact of flozins (SGLT2 inhibitors): an EAU Endourology review of risks, side effects and clinical considerations
Current results of studies on the use of flozins in patients with T2DM are promising for different spectrums of genitourinary diseases caused by different pathogenetic mechanisms. However, we need future clinical trials with specific drugs and comparisons to get trustworthy results about how helpful flozins are for these patients and whether they can be used in urology.
Authors
- Ali Talyshinskii (ORCID: https://orcid.org/0000-0002-3521-8937)
- Carlotta Nedbal (ORCID: https://orcid.org/0000-0003-2031-347X)
- Bhaskar K. Somani
Institutions
- Marche Polytechnic University (IT)
- European Association of Urology (NL)
- University Hospital Southampton NHS Foundation Trust (GB)
- Astana Medical University (KZ)
- ASST Fatebenefratelli Sacco (IT)
Publication Details
- Journal
- Current Opinion in Urology
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1097/mou.0000000000001306
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29